Spinal Delivery and Assessment of Drug Safety

Fundamental Neuropathology for Pathologists and Toxicologists: Principles and Techniques

Volumn , Issue , 2011, Pages 449-462

  Yaksh, Tony L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Applied toxicological neuropathology spinal delivery and drug safety assessment; Intrathecal agent toxicology; Spinal drug safety robust preclinical evaluations

Indexed keywords

EID: 84874598341     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470939956.ch27     Document Type: Chapter

References (108)

1. Howard-Jones N. A critical study of the origins and early development of hypodermic medication. J Hist Med Allied Sci. 1947;2:201-249.
2. Niemann N.Über eine neue organische Base in den Cocablattern. Gottingen, Germany; 1860.
3. Olch PD. William S. Halsted and local anesthesia: contributions and complications. Anesthesiology. 1975;42:479-486.
4. Pearce JM. Cotugno and cerebrospinal fluid. J Neurol Neurosurg Psychiatry. 2004;75:1299.
5. Hajdu SI. A note from history: discovery of the cerebrospinal fluid. Ann Clin Lab Sci. 2003;33:334-336.
6. Quincke H. Die Lumbalpunction des Hydrocephalus. Wiener Klini Wochenschrit. 1891;28:929-965.
7. Bier A. Versuche uber cocainisirunge Ruckenmarkes. Dtsch Z Chir. 1899;51:361-369.
8. BabcockWW. The technique of spinal anesthesia. NY J Med. 1914;50:637-702.
9. Tuffier T, Hallion F. Effects circulatoires des injections soudaracho de coca dans la regionlombaire. CR Hebd Seances Mem Soc Biol. 1990;52:897-899.
10. Morton AW. The subarachnoid injection of cocaine for operations on all parts of the body. Am Med. 1901;2:176-179.
11. Lusk WC. The anatomy of spinal puncture with some considerations on technic and paralytic sequels. Ann Surg. 1911;54:449-484.
12. Love JG. Continuous subarachnoid drainage for menigitis by means of a ureteral catheter. J Am Med Assoc. 1935;104: 1595-1597.
13. Tuohy EB. Continuous spinal anesthesia: a new method utilizing a ureteral catheter. Surg Clin N Am. 1945;25: 834-840.
14. Onofrio BM, et al. Continuous low-dose intrathecal morphine administration in the treatment of chronic pain of malignant origin. Mayo Clin Proc. 1981;56:516-520.
15. Yaksh TL, Rudy TA. Analgesia mediated by a direct spinal action of narcotics. Science. 1976;192:1357-1358.
16. Wang JK, et al. Pain relief by intrathecally applied morphine in man. Anesthesiology. 1979;50:149-151.
17. Wilson PR, Yaksh TL. Baclofen is antinociceptive in the spinal intrathecal space of animals. Eur J Pharmacol. 1978;51:323-330.
18. Campbell SK, et al. The effects of intrathecally administered baclofen on function in patients with spasticity. Phys Ther. 1995;75:352-362.
19. Bernards CM, Hill HF. Morphine and alfentanil permeability through the spinal dura, arachnoid, and pia mater of dogs and monkeys. Anesthesiology. 1990;73:1214-1219.
20. Schroth G, Klose U. Cerebrospinal fluid flow: I. Physiology of cardiac-related pulsation. Neuroradiology. 1992;35:1-9.
21. Schroth G, Klose U. Cerebrospinal fluid flow: II. Physiology of respiration-related pulsations. Neuroradiology. 1992;35:10-15.
22. Bernards CM. Cerebrospinal fluid and spinal cord distribution of baclofen and bupivacaine during slow intrathecal infusion in pigs. Anesthesiology. 2006;105:169-178.
23. Ummenhofer WC, et al. Comparative spinal distribution and clearance kinetics of intrathecally administered morphine, fentanyl, alfentanil, and sufentanil. Anesthesiology. 2000; 92:739-753.
24. Bernards CM. Understanding the physiology and pharmacology of epidural and intrathecal opioids. Best Pract Res Clin Anaesthesiol. 2002;16:489-505.
25. Yaksh TL, et al. Kinetic and safety studies on intrathecally infused recombinant-methionyl human brain-derived neurotrophic factor in dogs. Fundam Appl Toxicol. 1997;38: 89-100.
26. Kern SE, et al. The pharmacokinetics of the conopeptide contulakin-G (CGX-1160) after intrathecal administration: an analysis of data from studies in beagles. Anesth Analg. 2007;104:1514-1520.
27. Mack J, et al. Anatomy and development of the meninges: implications for subdural collections and CSF circulation. Pediatr Radiol. 2009;39:200-210.
28. Levy D. Migraine pain, meningeal inflammation, and mast cells. Curr Pain Headache Rep. 2009;13:237-240.
29. Yamate J, et al. Macrophage populations and expressions of regulatory proinflammatory factors in the rat meninx under lipopolysaccharide treatment in vivo and in vitro. Histol Histopathol. 2009;24:13-24.
30. Eisenach JC, et al. New epidural drugs: primum non nocere. Anesth Analg. 1998;87:1211-1212.
31. Rigler ML, et al. Cauda equina syndrome after continuous spinal anesthesia. Anesth Analg. 1991;72:275-281.
32. Schell RM, et al. Persistent sacral nerve root deficits after continuousspinalanaesthesia.CanJAnaesth.1991;38:908-911.
33. Schneider MC, et al. Transient neurologic toxicity after subarachnoid anesthesia with hyperbaric 5% lidocaine. Anesth Analg. 1994;79:610.
34. Snyder R, et al. More cases of possible neurologic toxicity associated with single subarachnoid injections of 5% hyperbaric lidocaine. Anesth Analg. 1994;78:411.
35. Arai T, Hoka S. Neurotoxicity of intrathecal local anesthetics. J Anesth. 2007;21:540-541.
36. Ross BK, et al. Local anesthetic distribution in a spinal model: a possible mechanism of neurologic injury after continuous spinal anesthesia. Reg Anesth. 1992;17:69-77.
37. Drasner K, et al. Persistent sacral sensory deficit induced by intrathecal local anesthetic infusion in the rat. Anesthesiology. 1994;80:847-852.
38. Sakura S, et al. The comparative neurotoxicity of intrathecal lidocaine and bupivacaine in rats. Anesth Analg. 2005;101:541-547.
39. Sakura S, et al. Local anesthetic neurotoxicity does not result from blockade of voltage-gated sodium channels. Anesth Analg. 1995;81:338-346.
40. Hashimoto K, et al. Comparative toxicity of glucose and lidocaine administered intrathecally in the rat. Reg Anesth Pain Med. 1998;23:444-450.
41. Ready LB, et al. Neurotoxicity of intrathecal local anesthetics in rabbits. Anesthesiology. 1985;63:364-370.
42. Yamashita A, et al. A comparison of the neurotoxic effects on the spinal cord of tetracaine, lidocaine, bupivacaine, and ropivacaine administered intrathecally in rabbits. Anesth Analg. 2003;97:512-519.
43. Malinovsky JM, et al. Intrathecal ropivacaine in rabbits: pharmacodynamic and neurotoxicologic study. Anesthesiology. 2002;97:429-435.
44. Ganem EM, et al. Neurotoxicity of subarachnoid hyperbaric bupivacaine in dogs. Reg Anesth. 1996;21:234-238.
45. Kroin JS, et al. The effect of chronic subarachnoid bupivacaine infusion in dogs. Anesthesiology. 1987;66:737-742.
46. Koizumi Y, et al. The effects of an AMPA receptor antagonist on the neurotoxicity of tetracaine intrathecally administered in rabbits. Anesth Analg. 2006;102:930-936.
47. Gold MS, et al. Lidocaine toxicity in primary afferent neurons from the rat. J Pharmacol Exp Ther. 1998;285:413-421.
48. Kitagawa N, et al. Possible mechanism of irreversible nerve injury caused by local anesthetics: detergent properties of local anesthetics and membrane disruption. Anesthesiology. 2004;100:962-967.
49. Yaksh TL. Spinal opiate analgesia: characteristics and principles of action. Pain. 1981;11:293-346.
50. Yaksh TL, et al. Studies of the pharmacology and pathology of intrathecally administered 4-anilinopiperidine analogues and morphine in the rat and cat. Anesthesiology. 1986;64: 54-66.
51. Sabbe MB, et al. Spinal delivery of sufentanil, alfentanil, and morphine in dogs: physiologic and toxicologic investigations. Anesthesiology. 1994;81:899-920.
52. Schuchard M. Neurologic sequelae of intraspinal drug delivery systems. Neuromodulation. 1998;1:137-148.
53. North RB, et al. Spinal cord compression complicating subarachnoid infusion of morphine: case report and laboratory experience. Neurosurgery. 1991;29:778-784.
54. Langsam A. Spinal cord compression by catheter granulomas in high-dose intrathecal morphine therapy: case report. Neurosurgery. 1999;44:689-691.
55. Cabbell KL, et al. Spinal cord compression by catheter granulomas in high-dose intrathecal morphine therapy: case report. Neurosurgery. 1998;42:1176-1180 (discussion: 1180-1171).
56. Blount JP, et al. Intrathecal granuloma complicating chronic spinal infusion of morphine: report of three cases. J Neurosurg. 1996;84:272-276.
57. Bejjani GK, et al. Intrathecal granuloma after implantation of a morphine pump: case report and review of the literature. Surg Neurol. 1997;48:288-291.
58. Aldrete JA, et al. Paraplegia in a patient with an intrathecal catheter and a spinal cord stimulator. Anesthesiology. 1994;81:1542-1545 (discussion: 1527A-1528A).
59. Coffey RJ, Burchiel K. Inflammatory mass lesions associated with intrathecal drug infusion catheters: report and observations on 41 patients. Neurosurgery. 2002;50:78-86 (discussion: 86-77).
60. Langman MJ, et al. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet. 1994;343:1075-1078.
61. Yaksh TL, et al. Chronically infused intrathecal morphine in dogs. Anesthesiology. 2003;99:174-187.
62. Gradert TL, et al. Safety of chronic intrathecal morphine infusion in a sheep model. Anesthesiology. 2003;99:188-198.
63. Allen JW, et al. Time course and role of morphine dose and concentration in intrathecal granuloma formation in dogs: a combined magnetic resonance imaging and histopathology investigation. Anesthesiology. 2006;105:581-589.
64. Allen JW, et al. Opiate pharmacology of intrathecal granulomas. Anesthesiology. 2006;105:590-598.
65. Stefano GB. Autoimmunovascular regulation: morphine and anandamide and ancondamide stimulated nitric oxide release. J Neuroimmunol. 1998;83:70-76.
66. Theoharides TC, et al. The role of mast cells in migraine pathophysiology. Brain Res Brain Res Rev. 2005;49:65-76.
67. Artico M, Cavallotti C. Catecholaminergic and acetylcholine esterase containing nerves of cranial and spinal dura mater in humans and rodents. Microsc Res Tech. 2001;53:212-220.
68. Bradding P, Holgate ST. Immunopathology and human mast cell cytokines. Crit Rev Oncol Hematol. 1990;31:119-133.
69. He S, Walls AF. Human mast cell tryptase: a stimulus of microvascular leakage and mast cell activation. Eur J Pharmacol. 1997;328:89-97.
70. Hermens JM, et al. Comparison of histamine release in human skin mast cells induced by morphine, fentanyl, and oxymorphone. Anesthesiology. 1985;62:124-129.
71. Feldberg W, Paton WD. Release of histamine from skin and muscle in the cat by opium alkaloids and other histamine liberators. J Physiol. 1951;114:490-509.
72. Blunk JA, et al. Opioid-induced mast cell activation and vascular responses is not mediated by mu-opioid receptors: an in vivo microdialysis study in human skin. Anesth Analg. 2004;98:364-370.
73. Yaksh TL, et al. The spinal biology in humans and animals of pain states generated by persistent small afferent input. Proc Natl Acad Sci USA. 1999;96:7680-7686.
74. Chen HS, Lipton SA. The chemical biology of clinically tolerated NMDA receptor antagonists. J Neurochem. 2006;97:1611-1626.
75. Hocking G, Cousins MJ. Ketamine in chronic pain management: an evidence-based review. Anesth Analg. 2003;97:1730-1739.
76. Subramaniam K, et al. Ketamine as adjuvant analgesic to opioids: a quantitative and qualitative systematic review. Anesth Analg. 2004;99:482-495.
77. Vranken JH, et al. Treatment of neuropathic cancer pain with continuous intrathecal administration of S {thorn}-ketamine. Acta Anaesthesiol Scand. 2004;48:249-252.
78. Kristensen JD, et al. The NMDA-receptor antagonist CPP abolishes neurogenic 'wind-up pain' after intrathecal administration in humans. Pain. 1992;51:249-253.
79. Stotz M, et al. Histological findings after long-term infusion of intrathecal ketamine for chronic pain: a case report. J Pain Symptom Manage. 1999;18:223-228.
80. Karpinski N, et al. Subpial vacuolar myelopathy after intrathecal ketamine: report of a case. Pain. 1997;73:103-105.
81. Malinovsky JM, et al. Is ketamine or its preservative responsible for neurotoxicity in the rabbit? Anesthesiology. 1993;78; 109-115.
82. Borgbjerg FM, et al. Histopathology after repeated intrathecal injections of preservative-free ketamine in the rabbit: a light and electron microscopic examination. Anesth Analg. 1994;79:105-111.
83. Errando CL, et al. Subarachnoid ketamine in swine-pathological findings after repeated doses: acute toxicity study. Reg Anesth Pain Med. 1999;24:146-152.
84. Vranken JH, et al. Severe toxic damage to the rabbit spinal cord after intrathecal administration of preservative-free S({thorn})-ketamine. Anesthesiology. 2006;105:813-818.
85. Kristensen JD, et al. Laser-Doppler evaluation of spinal cord blood flow after intrathecal administration of an Nmethyl-D-aspartate antagonist in rats. Anesth Analg. 1994; 78:925-931.
86. Hassenbusch SJ. Preclinical toxicity study of intrathecal administration of the pain relievers dextrorphan, dextromethorphan, and memantine in the sheep model. Neuromodulation. 1999;2:230-240.
87. Olney JW, et al. Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science. 1989;244:1360-1362.
88. Ikonomidou C, et al. Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain. Science. 1999;283:70-74.
89. Kitagawa N, et al. A proposed mechanism for amitriptyline neurotoxicity based on its detergent nature. Toxicol Appl Pharmacol. 2006;217:100-106.
90. Attwood D, Tolley JA. Self-association of analgesics in aqueous solution: association models for codeine, oxycodone, ethylmorphine and pethidine. J Pharm Pharmacol. 1980;32: 761-765.
91. Attwood D, Tolley JA. Self-association of analgesics in aqueous solution: micellar properties of dextropropoxyphene hydrochloride and methadone hydrochloride. J Pharm Pharmacol. 1980;32:533-536.
92. Yaksh TL, et al. Preclinical safety evaluation for spinal drugs. In: Yaksh T,ed. Spinal Drug Delivery. Amsterdam: Elsevier Science; 1999:417-437.
93. Yaksh TL, Allen JW. Preclinical insights into the implementation of intrathecal midazolam: a cautionary tale. Anesth Analg. 2004;98:1509-1511.
94. Allen JW, et al. An assessment of the antinociceptive efficacy of intrathecal and epidural contulakin-G in rats and dogs. Anesth Analg. 2007;104:1505-1513.
95. Yaksh TL, et al. Pharmacology and toxicology of chronically infused epidural clonidine. HCl in dogs. Fundam Appl Toxicol. 1994;23:319-335.
96. Yaksh TL, Malkmus SA. Animal models of intrathecal and epidural drug delivery. In:Yaksh TL,ed. Spinal Drug Delivery. Amsterdam: Elsevier Science; 1999:317-344.
97. Durant PA, Yaksh TL. Epidural injections of bupivacaine, morphine, fentanyl, lofentanil, and DADL in chronically implanted rats: a pharmacologic and pathologic study. Anesthesiology. 1986;64:43-53.
98. Lebeaux MI. Experimental epidural anaesthesia in the dog with lignocaine and bupivacaine. Br J Anaesth. 1973;45: 549-555.
99. Rodan BA, et al. Fibrous mass complicating epidural morphine infusion. Neurosurgery. 1985;16:68-70.
100. Yaksh TL, et al. Safety assessment of encapsulated morphine delivered epidurally in a sustained-release multivesicular liposome preparation in dogs. Drug Deliv. 2000;7:27-36.
101. Cohen SP, et al. Randomized, double-blind, placebo-controlled, dose-response, and preclinical safety study of transforaminal epidural etanercept for the treatment of sciatica. Anesthesiology. 2009;110:1116-1126.
102. Wermeling DP. Ziconotide, an intrathecally administered Ntype calcium channel antagonist for the treatment of chronic pain. Pharmacotherapy. 2005;25:1084-1094.
103. Yaksh TL. Ziconotide: a viewpoint by Tony L. Yaksh. CNS Drugs. 2006;20:340-341.
104. Eisenach JC, Yaksh TL. Safety in numbers: How do we study toxicity of spinal analgesics? Anesthesiology. 2002;97: 1047-1049.
105. Sabbe MB, et al. Toxicology of baclofen continuously infused into the spinal intrathecal space of the dog. Neurotoxicology. 1993;14:397-410.
106. Yaksh TL, et al. Inflammatory masses associated with intrathecal drug infusion: a review of preclinical evidence and human data. Pain Med. 2002;3:300-312.
107. Walker SM, Westin BD, Deumens R, Grafe M, Yaksh TL. Effects of intrathecal ketamine in the neonatal rat: evaluation of apoptosis and long-term functional outcome. Anesthesiology. 2010;113:147-159.
108. Westin BD, Walker SM, Deumens R, Grafe M, Yaksh TL. Validation of a preclinical spinal safety model: effects of intrathecal morphine in the neonatal rat. Anesthesiology. 2010;113:183-199.